Efficacy, tolerability and safety of cannabis‐based medicines for chronic pain management – An overview of systematic reviews

@article{Huser2018EfficacyTA,
  title={Efficacy, tolerability and safety of cannabis‐based medicines for chronic pain management – An overview of systematic reviews},
  author={W. H{\"a}user and F. Petzke and M. Fitzcharles},
  journal={European Journal of Pain},
  year={2018},
  volume={22}
}
Medicinal cannabis has already entered mainstream medicine in some countries. This systematic review (SR) aimed at evaluating the efficacy, acceptability and safety of cannabis‐based medicines for chronic pain management. Qualitative systematic review of SRs of randomized controlled trials with cannabis‐based medicines for chronic pain management. The Cochrane databases of SRs, Database of Abstracts of Reviews of Effects and PubMed were searched for SR published in the period January 2009 to… Expand
Cannabis-based medicines for chronic neuropathic pain in adults.
TLDR
To assess the efficacy, tolerability, and safety of cannabis-based medicines (herbal, plant-derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults, randomised, double-blind controlled trials are selected. Expand
European Pain Federation (EFIC) position paper on appropriate use of cannabis‐based medicines and medical cannabis for chronic pain management
TLDR
The quantity and quality of evidence are such that cannabis‐based medicines may be reasonably considered for chronic neuropathic pain and all other chronic pain conditions (cancer, non‐neuropathic noncancer pain). Expand
Efficacy and safety of paediatric medicinal cannabis use: A scoping review.
TLDR
There is a lack of evidence on the efficacy and safety of medicinal cannabis in most paediatric conditions. Expand
Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression
TLDR
Efficacy for neuropathic and non-neuropathic pain was similar, and pain intensity of chronic non-cancer patients was reduced by cannabinoids consumption, but effect sizes were small. Expand
[Position paper on medical cannabis and cannabis-based medicines in pain medicine].
TLDR
The increase in the number of countries with marketing authorisations or exemptions for medicinal cannabis or cannabis-based drugs for chronic pain will also pave the way for larger empirical and population-based studies that will further improve the evidence base of research and clinical use. Expand
Benefits and harms of medical cannabis: a scoping review of systematic reviews
TLDR
Results from the included reviews were mixed, with most reporting an inability to draw conclusions due to inconsistent findings and a lack of rigorous evidence, and it is possible the harms of cannabis-based medicines may outweigh benefits. Expand
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019
TLDR
The body of evidence for medical cannabis requires more rigorous evaluation before consideration as a treatment option for many conditions, and evidence necessary to inform policy and treatment guidelines is currently insufficient for many condition. Expand
Cannabis-based medicines for chronic pain management: current and future prospects.
TLDR
Although it is reasonable to consider cannabinoids for otherwise unresponsive pain, care should be taken in frail clinical populations, there is a pressing need for unbiased empirical data and high quality evidence to better inform prescribers and patients. Expand
Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain
TLDR
The current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain is outlined and limits on generalisability of previous findings are discussed. Expand
Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials
Abstract Objective To determine the benefits and harms of medical cannabis and cannabinoids for chronic pain. Design Systematic review and meta-analysis. Data sources MEDLINE, EMBASE, AMED, PsycInfo,Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Systematic review and meta-analysis of cannabis treatment for chronic pain.
TLDR
Systematic review and meta-analysis of double-blind randomized controlled trials that compared any cannabis preparation to placebo among subjects with chronic pain suggests that cannabis treatment is moderately efficacious for treatment of chronic pain, but beneficial effects may be partially (or completely) offset by potentially serious harms. Expand
[Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
TLDR
Cannabinoids were marginally superior to placebo in terms of efficacy and inferior interms of tolerability and safety and short-term and intermediate-term therapy with cannabinoids can be considered in selected patients with chronic neuropathic pain. Expand
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.
TLDR
There is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis and the context of the need for additional treatments for chronic pain is reviewed. Expand
The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.
TLDR
Cannabis-based medicinal extracts used in different populations of chronic nonmalignant neuropathic pain patients may provide effective analgesia in conditions that are refractory to other treatments. Expand
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
TLDR
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Expand
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
TLDR
The results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain and allow a strong recommendation for use and proposal as first-line treatment in neuropathicPain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin. Expand
[Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety].
TLDR
In the treatment of HIV cannabinoids were superior to placebo for the outcome of weight change, but not for treatment of cancer, and for the outcomes of tolerability the results were not significant. Expand
Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials
TLDR
This review adds further support that currently available cannabinoids are safe, modestly effective analgesics that provide a reasonable therapeutic option in the management of chronic non-cancer pain. Expand
Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.
TLDR
Use of marijuana for chronic pain, neuropathic pain, and spasticity due to multiple sclerosis is supported by high-quality evidence, and Physicians should educate patients about medical marijuana to ensure that it is used appropriately and that patients will benefit from its use. Expand
Cannabinoids for fibromyalgia.
TLDR
The primary outcomes in this review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverseEvents (safety). Expand
...
1
2
3
4
5
...